Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 11
2003 7
2004 6
2005 11
2006 10
2007 13
2008 10
2009 24
2010 30
2011 41
2012 41
2013 41
2014 59
2015 46
2016 40
2017 56
2018 81
2019 65
2020 76
2021 89
2022 89
2023 100
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

855 results

Results by year

Filters applied: . Clear all
Page 1
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. Among authors: xu z. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580297 Free PMC article. Clinical Trial.
RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative Breast Cancer to Radiotherapy.
Liu W, Zheng M, Zhang R, Jiang Q, Du G, Wu Y, Yang C, Li F, Li W, Wang L, Wu J, Shi L, Li W, Zhang K, Zhou Z, Liu R, Gao Y, Huang X, Fan S, Zhi X, Jiang D, Chen C. Liu W, et al. Among authors: zhi x. Adv Sci (Weinh). 2023 Feb;10(5):e2203884. doi: 10.1002/advs.202203884. Epub 2022 Dec 23. Adv Sci (Weinh). 2023. PMID: 36563124 Free PMC article.
The Transcriptome and DNA Methylome Landscapes of Human Primordial Germ Cells.
Guo F, Yan L, Guo H, Li L, Hu B, Zhao Y, Yong J, Hu Y, Wang X, Wei Y, Wang W, Li R, Yan J, Zhi X, Zhang Y, Jin H, Zhang W, Hou Y, Zhu P, Li J, Zhang L, Liu S, Ren Y, Zhu X, Wen L, Gao YQ, Tang F, Qiao J. Guo F, et al. Among authors: zhi x. Cell. 2015 Jun 4;161(6):1437-52. doi: 10.1016/j.cell.2015.05.015. Cell. 2015. PMID: 26046443 Free article.
PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study.
Kong Y, Zhao X, Xu M, Pan J, Ma Y, Zou L, Peng Q, Zhang J, Su C, Xu Z, Zhou W, Peng Y, Yang J, Zhou C, Li Y, Guo Q, Chen G, Wu H, Xing P, Zhang L. Kong Y, et al. Among authors: xu z. Front Immunol. 2022 Jul 8;13:952066. doi: 10.3389/fimmu.2022.952066. eCollection 2022. Front Immunol. 2022. PMID: 35874780 Free PMC article. Clinical Trial.
N6-methyladenosine (m6A) modification in hepatocellular carcinoma.
Ma H, Hong Y, Xu Z, Weng Z, Yang Y, Jin D, Chen Z, Yue J, Zhou X, Xu Z, Fei F, Li J, Song W. Ma H, et al. Among authors: xu z. Biomed Pharmacother. 2024 Apr;173:116365. doi: 10.1016/j.biopha.2024.116365. Epub 2024 Mar 6. Biomed Pharmacother. 2024. PMID: 38452654 Free article. Review.
855 results